Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2024 02:05 ET | Source: Boehringer Ingelheim

CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction...
March 19, 2024 07:00 ET | Source: Boehringer Ingelheim

SPEVIGO® approved for expanded indications in China and the US

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China,...